OncoMed Pharmaceuticals Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Employees
-
22
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$53.4M
OncoMed Pharmaceuticals General Information
Description
OncoMed Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's therapeutic candidates and preclinical programs include Navicixizumab, Anti-TIGIT, GITRL-Fc, and Rosmantuzumab.
Contact Information
Website
www.oncomed.comCorporate Office
- 800 Chesapeake Drive
- Redwood City, CA 94063
- United States
Corporate Office
- 800 Chesapeake Drive
- Redwood City, CA 94063
- United States
OncoMed Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Merger/Acquisition | 23-Apr-2019 | $53.4M | Completed | Generating Revenue | ||
| 13. Secondary Transaction - Open Market | 23-Apr-2018 | Completed | Profitable | |||
| 12. Secondary Transaction - Open Market | 25-Apr-2016 | Completed | Profitable | |||
| 11. Secondary Transaction - Open Market | 25-Apr-2015 | Completed | Profitable | |||
| 10. IPO | 18-Jul-2013 | Completed | Generating Revenue | |||
| 9. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 8. Later Stage VC | Completed | Generating Revenue | ||||
| 7. Grant | 02-Nov-2010 | Completed | Generating Revenue | |||
| 6. Grant | 31-Dec-2009 | $240K | $179M | Completed | Generating Revenue | |
| 5. Later Stage VC (Series B1) | 30-Jan-2009 | $103M | $179M | Completed | Generating Revenue |
OncoMed Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B3 | ||||||||
| Series B2 | ||||||||
| Series B | 31,874,999 | $0.001000 | 8% | $1.4 | $1.4 | 1x | $1.4 | 23.63% |
| Series A | 18,000,000 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 13.35% |
OncoMed Pharmaceuticals Comparisons
Industry
Financing
Details
OncoMed Pharmaceuticals Competitors (76)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Nimbus Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Immunome | Formerly VC-backed | Bothell, WA |
OncoMed Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
OncoMed Pharmaceuticals Patents
OncoMed Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019380595-A1 | Methods and monitoring of treatment with vegf/dll4 binding agent | Inactive | 15-Nov-2018 | ||
| EP-3880697-A2 | Methods and monitoring of treatment with vegf/dll4 binding agent | Inactive | 15-Nov-2018 | ||
| CA-3119458-A1 | Methods and monitoring of treatment with vegf/dll4 binding agent | Pending | 15-Nov-2018 | ||
| US-20180222958-A1 | Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof | Inactive | 20-Dec-2016 | ||
| AU-2017368155-B2 | Methods for treatment of cancer comprising tigit-binding agents | Active | 30-Nov-2016 | C07K14/47 |
OncoMed Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
OncoMed Pharmaceuticals Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adams Street Partners | PE/Buyout | Minority | ||
| Bay Partners | Venture Capital | Minority | ||
| De Novo Ventures | Venture Capital | Minority | ||
| Delphi Ventures | Venture Capital | Minority | ||
| Foresite Capital | Growth/Expansion | Minority |
OncoMed Pharmaceuticals FAQs
-
When was OncoMed Pharmaceuticals founded?
OncoMed Pharmaceuticals was founded in 2004.
-
Who is the founder of OncoMed Pharmaceuticals?
Max Wicha MD and Michael Clarke MD are the founders of OncoMed Pharmaceuticals.
-
Where is OncoMed Pharmaceuticals headquartered?
OncoMed Pharmaceuticals is headquartered in Redwood City, CA.
-
What is the size of OncoMed Pharmaceuticals?
OncoMed Pharmaceuticals has 22 total employees.
-
What industry is OncoMed Pharmaceuticals in?
OncoMed Pharmaceuticals’s primary industry is Drug Discovery.
-
Is OncoMed Pharmaceuticals a private or public company?
OncoMed Pharmaceuticals is a Private company.
-
What is the current valuation of OncoMed Pharmaceuticals?
The current valuation of OncoMed Pharmaceuticals is .
-
What is OncoMed Pharmaceuticals’s current revenue?
The current revenue for OncoMed Pharmaceuticals is .
-
How much funding has OncoMed Pharmaceuticals raised over time?
OncoMed Pharmaceuticals has raised $261M.
-
Who are OncoMed Pharmaceuticals’s investors?
Adams Street Partners, Bay Partners, De Novo Ventures, Delphi Ventures, and Foresite Capital are 5 of 16 investors who have invested in OncoMed Pharmaceuticals.
-
Who are OncoMed Pharmaceuticals’s competitors?
CytomX Therapeutics, NexImmune, NGM Biopharmaceuticals, Nimbus Therapeutics, and Immunome are some of the 76 competitors of OncoMed Pharmaceuticals.
-
When was OncoMed Pharmaceuticals acquired?
OncoMed Pharmaceuticals was acquired on 23-Apr-2019.
-
Who acquired OncoMed Pharmaceuticals?
OncoMed Pharmaceuticals was acquired by Mereo Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
